Core Viewpoint - Flux Power Holdings, Inc. has announced a public offering of 3,840,000 shares at a price of $2.50 per share, aiming to raise approximately $9.6 million before expenses [1]. Group 1: Offering Details - The public offering consists of 3,840,000 shares priced at $2.50 each, with an additional option for the underwriter to purchase up to 576,000 shares [1]. - The gross proceeds from the offering are expected to be around $9.6 million, excluding any additional shares purchased by the underwriter [1]. - The offering is set to close on November 3, 2025, pending customary closing conditions [1]. Group 2: Underwriter Information - Lake Street Capital Markets, LLC is serving as the sole book-running manager for the offering [2]. Group 3: Regulatory Compliance - A registration statement for the shares has been filed with the U.S. Securities and Exchange Commission (SEC) and became effective on October 29, 2025 [3]. - The offering is being conducted solely through a prospectus, with a preliminary prospectus already filed with the SEC [3]. Group 4: Company Overview - Flux Power designs, manufactures, and sells advanced lithium-ion energy storage solutions for various industrial and commercial applications [5]. - The company's products, including lithium-ion battery packs and proprietary battery management systems, offer a more efficient and environmentally friendly alternative to traditional lead-acid and propane solutions [5]. - Flux Power's solutions contribute to reduced CO2 emissions and improved sustainability metrics for fleets [5].

Core Viewpoint - Corbus Pharmaceuticals Holdings, Inc. has announced a public offering of approximately $75 million, consisting of 4,744,231 shares of common stock priced at $13.00 per share and pre-funded warrants for 1,025,000 shares priced at $12.9999 each, with the offering expected to close on or about November 3, 2025 [1][2]. Group 1: Offering Details - The total public offering size is approximately $75 million before deducting underwriting discounts and estimated offering expenses [1]. - The exercise price of the pre-funded warrants is set at $0.0001 per share [1]. - Corbus has granted underwriters a 30-day option to purchase up to an additional 865,384 shares on the same terms [1]. Group 2: Use of Proceeds - The net proceeds from the offering will be used to fund the clinical development of Corbus' pipeline, as well as for working capital and other general corporate purposes [2]. Group 3: Company Overview - Corbus Pharmaceuticals is focused on oncology and obesity, with a diversified portfolio aimed at addressing serious illnesses through innovative scientific approaches [5]. - The company's pipeline includes CRB-701, CRB-601, and CRB-913, targeting cancer and obesity treatments [5].

Core Viewpoint - NexMetals Mining Corp. has increased the size of its public offering from C$65 million to C$80 million due to strong demand from institutional investors, marking the second upsizing of the offering [1][3]. Offering Details - The offering will consist of up to 14,035,100 Units, with no over-allotment option available [3]. - Agents will receive a cash fee of 6% of the gross proceeds, with a reduced fee of 2% for sales to certain individuals on a "president's list" for gross proceeds up to C$7 million [3]. - Each Unit will include one common share and one common share purchase warrant, allowing the holder to acquire one common share at a price of C$8.00 for 24 months following issuance [3]. Use of Proceeds - The net proceeds from the offering are intended for the prepayment of the first contingent milestone payment under the Asset Purchase Agreement for the Selebi and Selkirk mines, exploration and development activities in Botswana, and general corporate purposes [4]. Closing Timeline - The offering is expected to close on or about November 13, 2025, pending necessary approvals [5]. Company Overview - NexMetals Mining Corp. focuses on the redevelopment of previously producing copper, nickel, and cobalt resources in Botswana [7]. - The company's team has extensive experience in mine discovery and development, with senior members averaging over 20 years in the industry [9].

Core Points - Veru Inc. announced a public offering of 1,400,000 shares of common stock, pre-funded warrants for 7,000,000 shares, and Series A and B warrants for 8,400,000 shares each, with a combined offering price of $3.00 per share [1][2] - The gross proceeds from the offering are expected to be approximately $25.2 million, with potential additional proceeds of about $50.4 million if all warrants are exercised [2] - The net proceeds will primarily fund the development of enobosarm, particularly for the Phase 2b PLATEAU clinical study, and will also cover working capital and general corporate purposes [3] Offering Details - The offering includes common stock, pre-funded warrants, and Series A and B warrants, all sold by Veru under a previously filed shelf registration statement [4] - The offering is expected to close on or about October 31, 2025, pending customary closing conditions [1] Company Overview - Veru Inc. is a late clinical stage biopharmaceutical company focused on innovative medicines for cardiometabolic and inflammatory diseases [6]

Core Viewpoint - Cleveland-Cliffs Inc. has announced a public offering of 75,000,000 common shares, aiming for gross proceeds of approximately $964 million before discounts and expenses, with a potential additional 11,250,000 shares available for purchase by the underwriter [1][2]. Group 1: Offering Details - The offering is expected to close on October 31, 2025, pending customary closing conditions [1]. - The net proceeds from the offering will primarily be used to repay borrowings under the company's asset-based credit facility, with any remaining funds allocated for general corporate purposes [2]. - UBS Securities LLC is acting as the underwriter for the offering, which will be available for sale on the New York Stock Exchange and other markets at prevailing market prices [3]. Group 2: Company Overview - Cleveland-Cliffs is a leading North American steel producer, focusing on value-added sheet products, particularly for the automotive industry [6]. - The company is vertically integrated, covering the entire process from iron ore mining to steelmaking and downstream processing [6]. - Headquartered in Cleveland, Ohio, Cleveland-Cliffs employs approximately 30,000 people across its operations in the United States and Canada [6].

Core Viewpoint - VSE Corporation has priced its public offering of common stock, aiming to raise approximately $384 million to fund its acquisition of Aero 3 and support future strategic acquisitions [1][2]. Group 1: Offering Details - VSE Corporation is offering 2,352,941 shares of common stock at a price of $170.00 per share [1]. - The underwriters have a 30-day option to purchase an additional 352,941 shares [1]. - The offering is expected to close on October 29, 2025, pending customary closing conditions [1]. Group 2: Use of Proceeds - The net proceeds from the offering are expected to be approximately $384 million after deducting underwriting discounts and commissions [2]. - VSE intends to use the proceeds to fund the cash consideration for the acquisition of Aero 3, support potential future strategic acquisitions, and for general corporate purposes [2]. Group 3: Underwriters - Jefferies and Morgan Stanley are acting as joint lead book-running managers for the offering [3]. - RBC Capital Markets and William Blair are serving as joint book-runners, while Truist Securities, B. Riley Securities, and Stifel are additional book-runners [3]. - KeyBanc Capital Markets, Benchmark, a StoneX Company, and Jones are co-managers for the offering [3]. Group 4: Company Overview - VSE Corporation is a leading provider of aviation aftermarket distribution and repair services, focused on enhancing the productivity and longevity of high-value assets [6]. - The company is headquartered in Miramar, Florida, and supports engine component and airframe accessory part distribution and repair services for commercial and business aviation operators [6].

RT Alex Svanevik 🐧 (@ASvanevik)Go public.On the internet. https://t.co/DBPCc2yVHP ...

Core Viewpoint - X4 Pharmaceuticals has announced a public offering of 45,860,000 shares of common stock priced at $2.90 per share, aiming to raise approximately $135 million to fund the development of its drug mavorixafor and for general corporate purposes [1][2]. Group 1: Offering Details - The public offering includes pre-funded warrants for up to 700,000 shares at a price of $2.899 each, with an exercise price of $0.001 per share [1]. - The offering is expected to close on October 27, 2025, pending customary closing conditions [1]. - Underwriters have a 30-day option to purchase an additional 6,984,000 shares at the public offering price [1]. Group 2: Use of Proceeds - The net proceeds from the offering will be used to fund the pivotal Phase 3 development of mavorixafor for chronic neutropenic disorders, along with general administrative expenses, capital expenditures, and working capital [2]. Group 3: Company Background - X4 Pharmaceuticals focuses on developing therapies for rare hematology diseases, with mavorixafor being an orally available CXCR4 antagonist currently marketed in the U.S. as XOLREMDI® [5]. - The company is conducting a global Phase 3 clinical trial (4WARD) for mavorixafor in patients with chronic neutropenic disorders [5].

Core Points - RAPT Therapeutics, Inc. has initiated an underwritten public offering of its common stock, with an option for underwriters to purchase an additional 15% of the total shares offered [1] - The offering is subject to market conditions and there is no assurance regarding its completion or the actual size and terms [1] - The offering is made under a shelf registration statement filed with the SEC, which was declared effective on August 17, 2023 [3] Company Overview - RAPT is a clinical-stage immunology-based biopharmaceutical company focused on developing novel therapies for inflammatory and immunological diseases [5] - The company utilizes proprietary expertise in immunology to create therapies aimed at modulating critical immune responses [5] Offering Details - Joint bookrunning managers for the offering include Leerink Partners, TD Cowen, Guggenheim Securities, Wells Fargo Securities, and LifeSci Capital [2] - Lead managers for the offering are H.C. Wainwright & Co. and Clear Street [2] - A preliminary prospectus supplement and accompanying prospectus will be filed with the SEC and made available on their website [3]

Core Viewpoint - Praxis Precision Medicines, Inc. has announced a public offering of 3,025,480 shares of common stock priced at $157.00 per share, along with pre-funded warrants for an additional 318,470 shares, aiming to raise approximately $525 million in gross proceeds before expenses [1] Group 1: Offering Details - The offering includes 3,025,480 shares of common stock priced at $157.00 each and pre-funded warrants to purchase up to 318,470 shares at a price of $156.9999 per warrant [1] - The gross proceeds from the offering are expected to be around $525 million, excluding underwriting discounts and commissions [1] - Praxis has granted underwriters a 30-day option to purchase up to 501,592 additional shares at the public offering price [1] Group 2: Underwriters - TD Cowen, Piper Sandler, Guggenheim Securities, and Truist Securities are acting as joint book-running managers for the offering [2] - Oppenheimer & Co. and H.C. Wainwright & Co. are serving as lead managers for the offering [2] Group 3: Regulatory Information - The offering is made under a shelf registration statement on Form S-3ASR, which became effective upon filing with the SEC on December 23, 2024 [3] - A preliminary prospectus supplement was filed with the SEC on October 16, 2025, with the final prospectus supplement to be filed subsequently [3]